Why Your Dietary Supplement May Be Reclassified as a Medicinal Product — and What to Do About It in 2026
Note: All figures are in Russian rubles (₽). For reference: 1 USD ≈ 100 RUB as of early 2026. Dollar equivalents are given at first mention of each specific amount.
In January 2026, Rospotrebnadzor revoked State Registration Certificates (SRCs) for dietary supplements (BAA) containing melatonin and simethicone. Within a single week, more than 150 trade names disappeared from pharmacy shelves and online marketplaces.
Manufacturers were left with stock they could only dispose of or re-register through an entirely different, far more demanding procedure. The reason: both substances had crossed into medicinal territory. Dosages previously treated as nutritional are now recognized as therapeutic. And melatonin is far from the only substance affected.
This article examines where the boundary between a dietary supplement (BAA) and a medicinal product actually lies, why that boundary keeps shifting, and how to avoid a situation where an entire business collapses because of one wrong call at the product development stage.
Blurred Boundaries and the Grey Zone
Until 2020, the Russian dietary supplement market operated under weak oversight. Formally, products had to comply with the Technical Regulation of the Customs Union TR CU 021/2011 «On Food Safety,» but enforcement was patchy. Many manufacturers registered products with therapeutic dosages of active substances as supplements, saving themselves the cost of clinical trials and expert assessments.
The main loophole was terminological. A dietary supplement is formally intended to «replenish nutrient deficiencies» and «maintain bodily functions.» A medicine treats. But where does maintenance end and treatment begin? Manufacturers exploited this ambiguity, releasing products with high concentrations of vitamins, minerals, and plant extracts. Labels read «promotes normalization,» «supports health,» «source of bioflavonoids» — nothing that constituted a direct medical claim.
A separate problem was the so-called «Armenian scheme.» An SRC issued in one member state of the EAEU (Eurasian Economic Union) is valid across the entire Union. Products with formulations that would never pass Russian scrutiny were registered in Armenia and then sold in Russia under that SRC. By expert estimates, illegal turnover — counterfeit products, unregistered supplements, and mislabelled goods on marketplaces — accounted for 20–45% of the market in 2023.
Digital Control and the New Rules of the Game
By 2026, the market had changed fundamentally. A fully operational end-to-end traceability system made the sale of unregistered products through any legal channel technically impossible.
Federal Law No. 150-FZ
The defining regulatory event of 2025 was the enactment of Federal Law No. 150-FZ of June 7, 2025 «On Amendments to Certain Legislative Acts of the Russian Federation.» The law amended FL-323 «On the Fundamentals of Public Health Protection» and FL-29 «On the Quality and Safety of Food Products,» adding Article 25.7 governing the use of dietary supplements specifically.
From September 1, 2025, physicians gained the right to prescribe dietary supplements to patients. Previously, specialists worked in a legal vacuum: clinical guidelines included nutritional support, but the formal prescription of «food products» fell outside the standard of medical care.
The legislator established three mandatory conditions for such prescriptions: the product must appear in a dedicated Ministry of Health registry approved by Rospotrebnadzor; it must meet elevated quality and efficacy standards set by the Government of the Russian Federation; and the prescription must align with the indications approved in official methodological guidelines.
The market has effectively split into «clinical supplements» backed by an evidentiary base and «consumer supplements» for over-the-counter sale. The law also introduced anti-corruption restrictions: physicians are prohibited from receiving compensation from manufacturers in exchange for prescriptions, entering into promotional agreements, or accepting product samples to pass on to patients.
Legal Distinction: Supplement vs. Medicinal Product
TR CU 021/2011 defines a dietary supplement as a natural or nature-identical biologically active substance intended for consumption alongside food or for incorporation into food products. The stated purpose is to replenish nutrient deficiencies and maintain bodily functions within physiological limits.
Federal Law No. 61-FZ of April 12, 2010 «On the Circulation of Medicinal Substances» defines a medicinal product as a substance or combination of substances intended for the treatment, prevention, or diagnosis of diseases, possessing a proven therapeutic effect.
The difference determines everything downstream. A dietary supplement is classified as a food product and regulated by Rospotrebnadzor. A medicinal product falls under the Ministry of Health of the Russian Federation and requires a fundamentally different level of proof of efficacy and safety.
Dosage as the Dividing Line
The baseline rule of TR CU 021/2011: the content of biologically active substances in the daily dose of a dietary supplement must fall between 10% and 50% of the single therapeutic dose established for those substances when used as medicinal products.
If the daily dose of an active component exceeds the Upper Limit (UL), the product automatically falls outside the dietary supplement category. Rospotrebnadzor will refuse to issue an SRC.
Case study: Vitamin D3
Vitamin D3 (cholecalciferol) illustrates the regulatory logic clearly. During the pandemic years, the market filled with high-dose supplements — 5,000 IU, 10,000 IU — registered as dietary supplements. By 2026, that practice has been stopped entirely.
Table 1: Vitamin D3 Dosage Thresholds by Legal Status
| Category | Daily Dosage | Legal Status | Notes |
|---|---|---|---|
| Standard dietary supplement | Up to 2,000 IU (50 mcg) | SRC | Deficiency prevention. Safe for long-term use without medical supervision. |
| Borderline zone | 2,000–4,000 IU | SRC with restrictions | Safety justification required. Label typically reads «on medical advice.» |
| Medicinal product | Over 4,000–5,000 IU | Marketing Authorization (MA) | Therapeutic doses for treating osteoporosis and rickets. Supplements at 5,000 IU and above are subject to withdrawal. |
| Bolus doses | 20,000–50,000 IU | Prescription medicine (Rx) | Weekly or monthly administration. Prohibited for dietary supplements due to hypercalcaemia risk. |
The recommended daily intake under TR CU 022/2011 is 5 mcg (200 IU). The Upper Limit for adults is set at 100 mcg (4,000 IU). Meanwhile, clinical guidelines from endocrinologists recommend 2,000 IU for maintaining adequate vitamin D levels, and 4,000–7,000 IU per day for correcting established deficiency.
The result is a gap: what medicine requires cannot always be purchased as a dietary supplement. Rospotrebnadzor’s position is firm — bolus formats (high concentration with a recommendation for infrequent use) are unacceptable for supplements because they create a genuine risk of consumer misuse.
Other Micronutrients Under Regulatory Scrutiny
Vitamin B6 has had its maximum supplement level reduced. Prolonged intake of high doses causes neuropathy; the German Federal Institute for Risk Assessment (BfR) recommends a supplement limit of 0.9 mg per day.
Selenium is subject to a strict upper limit due to the risk of selenosis. The cap for dietary supplements is up to 255 mcg per day for adults, with a common safety target of 40–50 mcg in practice.
Vitamin A (retinol) is tightly controlled due to teratogenic effects and hepatotoxicity. The UL for adults is 3,000 mcg RE per day.
Prohibited Components
Annex 7 of TR CU 021/2011 lists the plants, animal-origin materials, and biologically active substances prohibited from use in dietary supplements. The list expanded considerably in 2024–2025.
Ashwagandha (Withania somnifera) was added under Section 1.1, item 63. Despite its popularity in Ayurvedic medicine and widespread use in Western markets, it is banned for dietary supplements in the EAEU. Danish and German regulatory bodies — the DTU Food Institute and BfR — have documented negative effects on thyroid and reproductive function, as well as risks of pregnancy termination. From September 1, 2025, product listings that mention Withania somnifera are systematically removed from Russian marketplaces.
Kava-kava (Piper methysticum) sits in criminal law territory. Listed as a plant containing psychotropic, narcotic, potent, or toxic substances, its import and sale in supplement form constitutes smuggling of potent substances under Article 226.1 of the Criminal Code of the Russian Federation.
Ephedra is classified as a potent, narcotic, and psychotropic plant and can only be registered as a prescription medicinal product. Coca leaves are similarly prohibited; Roskachestvo identified over 400 products on Russian marketplaces in 2024 claiming to contain these components.
A separate risk category is supplements for weight loss and men’s health that contain undeclared pharmaceutical APIs. Modern laboratory methods detect synthetic PDE-5 inhibitors (sildenafil, tadalafil) and anorexigens (sibutramine) even in trace amounts. Detection triggers SRC revocation, batch-level blocking through the marking system, and criminal proceedings under Article 238.1 of the Criminal Code.
Labelling and Marketplace Compliance
By 2026, the circulation of dietary supplements has moved entirely into the digital domain. Three systems are integrated: the Chestny ZNAK («Honest Mark») product marking system, Rospotrebnadzor and EEC (Eurasian Economic Commission) registries, and the internal algorithms of the major marketplaces.
Permissive Mode at the Point of Sale
From November 1, 2024, «Permissive Mode» became mandatory for dietary supplement retail. When a cashier scans the Data Matrix code on packaging, the POS software sends a query to the GIS MT Chestny ZNAK system. The system verifies the code in 1.5 seconds; if the check passes, the fiscal receipt is generated. If not, the sale is blocked automatically.
Automatic blocking is triggered when the code is not found in the database (indicating counterfeit), when the code has already been withdrawn from circulation (indicating resale), when the product’s expiry date has passed, or when Rospotrebnadzor has issued a blocking decision. If Rospotrebnadzor suspends an SRC for a specific batch or trade name, every code in that batch is blocked across the system instantly. The product cannot be sold through any legal outlet in the country.
New Marketplace Regulations
The Law «On Certain Issues of Regulating the Platform Economy in the Russian Federation,» entering full force in October 2026, makes marketplaces subsidiarily liable for the quality of goods they sell.
New listing rules for dietary supplements on Wildberries, Ozon, and Yandex Market require API validation of the SRC. From September 1, 2026, each product card must link to the entry in the Unified Registry of State Registration Certificates, with real-time SRC validity checks running automatically. Uploading counterfeit certificates has become pointless.
NLP (Natural Language Processing) algorithms scan product descriptions. Words such as «treatment,» «drug,» «painkiller,» and «for blood pressure» trigger automatic listing suspension or seller fines. Fines for marketplaces reach ₽300,000 (~$3,000) per verified case of unlicensed supplement sales.
Extrajudicial Website Blocking
Under amendments to the «Law on Information» introduced by Federal Law No. 150-FZ, Rospotrebnadzor may now add pages to the Roskomnadzor blocked-resources registry without a court order. Grounds for blocking include offering supplements with prohibited components, absence of Data Matrix marking, and advertising retail sales of restricted supplements.
Comparing Registration Procedures
The choice between registering a product as a dietary supplement (SRC) or a medicinal product (MA — Marketing Authorization) determines its entire commercial future. Although state fees for medicines were reduced in 2025, the total cost of bringing a medicinal product to market remains an order of magnitude higher.
Table 2: Dietary Supplement SRC vs. Medicinal Product MA — Registration Comparison
| Parameter | Dietary Supplement (SRC) | Medicinal Product (MA) |
|---|---|---|
| Regulator | Rospotrebnadzor | Ministry of Health |
| Timeline | 2–4 months | 10–24 months |
| State fee | ₽5,000 (~$50) | ₽190,000–₽420,000 (~$1,900–$4,200) |
| Turnkey cost | ₽90,000–₽450,000 (~$900–$4,500) | From ₽1,400,000 (~$14,000) + clinical trials from ₽5,000,000 (~$50,000) |
| Clinical trials | Generally not required | Mandatory |
| Certificate validity | Indefinite | 5 years (initial registration) |
| Manufacturing standards | HACCP / ISO 22000 | EAEU GMP — Good Manufacturing Practice (Minpromtorg inspection) |
| Pricing | Free market | Regulated for VED list (Vital and Essential Drugs) |
| Marketing scope | Restricted | Broad |
If a medicinal product enters the VED list, its price is fixed by the state. Dietary supplements operate under free-market pricing, which makes the category attractive for launching innovative products — provided the formulation stays within the regulatory boundaries.
What the Label Can and Cannot Say
TR CU 022/2011 «Food Products in Terms of Their Labelling» and the Federal Law «On Advertising» together define a narrow corridor of permissible language.
Prohibited claims include «painkiller,» «treats arthritis,» «lowers cholesterol,» «eliminates insomnia,» and «preparation» or «drug.» Permitted claims include «helps reduce tension,» «supports normal cholesterol levels,» «additional source of chondroitin,» and «source of flavonoids.»
The Federal Antimonopoly Service (FAS) runs automated online monitoring of dietary supplement advertising. Fines for violations reach ₽500,000 (~$5,000) per incident for legal entities.
Every advertisement and every label for a dietary supplement must carry the disclaimer: «Not a medicinal product.» In digital advertising, this disclaimer must occupy at least 10% of the ad space.
Action Plan for Manufacturers
Getting product classification right at the outset saves millions. A mistake costs not only the money spent on disposing of stock, but also market reputation.
Start with a formula audit. Cross-reference every component against Annex 7 of TR CU 021/2011 for prohibited substances. Check the dosages of all active ingredients — particularly vitamin D3, vitamin A, selenium, and B6 — against the applicable Upper Limits. Products in the «red zone» (for example, D3 at 5,000 IU) must either be re-registered as medicinal products or withdrawn from the market.
Next, verify the product name. A dietary supplement’s name must not mislead consumers or be phonetically similar to any registered medicinal product. The State Registry of Medicinal Products is available at grls.rosminzdrav.ru.
Review all marketing materials. Remove any claims related to the treatment, prevention, or diagnosis of disease. Confirm that the «Not a medicinal product» disclaimer appears on every advertising asset.
Ensure digital transparency. Synchronise SRC data with marketplace product cards and verify SRC validity in the EEC registry at eec.eaeunion.org and the Rospotrebnadzor registry at fp.crc.ru. Confirm that your retail partners’ POS software is configured for the 1.5-second Permissive Mode response.
Finally, consider the clinical strategy. If the product is intended for inclusion in the Ministry of Health’s approved prescribing list, investment in an evidentiary base is required. This carries costs, but it opens access to the most receptive prescribing audience.
Attempting to slip through as a dietary supplement with therapeutic dosages risks stock seizure, marketplace delisting, and criminal liability in cases involving prohibited components.
In 2026, the line between a dietary supplement and a medicinal product is a line of code embedded in every POS terminal and marketplace server.
Sources: TR CU 021/2011 «On Food Safety,» including Annex 7 (prohibited components); TR CU 022/2011 «Food Products in Terms of Their Labelling»; Federal Law No. 61-FZ of April 12, 2010 «On the Circulation of Medicinal Substances»; Federal Law No. 323-FZ of November 21, 2011 «On the Fundamentals of Public Health Protection»; Federal Law No. 29-FZ of January 2, 2000 «On the Quality and Safety of Food Products»; Federal Law No. 150-FZ of June 7, 2025 «On Amendments to Certain Legislative Acts of the Russian Federation»; Physiological Intake Norms MR 2.3.1.0253-21; expert estimates of illegal market share, 2023; Roskachestvo marketplace monitoring report, 2024; BfR (German Federal Institute for Risk Assessment) guidance on vitamin B6; DTU Food Institute (Denmark) assessment of Withania somnifera.
Other articles on Regulatory Affairs →